Placebo-controlled First-in-Human Study of Oral TQS-168 in Healthy Volunteers

This first-in-human study provided data on safety, tolerability, and PK data for TQS-168.

TQS-168, a first-in-class small-molecule inducer of peroxisome proliferator-activated receptor gamma coactivator 1-alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis.

A single-ascending-dose and multiple-ascending-dose (SAD/MAD study) of TQS-168 was carried out in healthy male volunteers to investigate the safety, tolerability, pharmacokinetics (PK), food effect, and preliminary pharmacodynamic effects (PD). 

This study demonstrated that TQS-168, a novel PGC-1α enhancer, is well tolerated in humans at oral doses that produce plasma exposures in the therapeutic range.

As part of this program, we also successfully evaluated three different formulations and selected a lead spray-dried dispersion formulation for future patient studies.

Download this poster to learn how Translational Pharmaceutics and clinical pharmacology services from Quotient Sciences reduces development risks and maximizes the probability of success.